Research NOW

Anticancer Agent Offers Hope for Targeting Drug-Resistant Solid Tumors

Tony-OlszanskiPhase Ib clinical trial of three combination therapies for a broad range of solid tumors holds promise for overcoming resistance to currently available cancer drugs and expanding personalized treatment options. At the center of the trial is a compound called MLN2480, whose clinical development was made possible by a partnership between Fox Chase Cancer Center and Millennium Pharmaceuticals. Continue Reading »

Knowledge of Type II Kinase Inhibition May Help Improve Drug Design

THE TOPLINE Type II kinase inhibitors include a number of drugs showing promise in both the clinic and trials Developing additional Type II kinase inhibitors will likely improve the quality of the current anticancer drug cache Molecular factors that determine why important classes of cancer drugs are specific for their kinases are providing a rich data resource that can be used to create new, clinically useful kinase inhibitors—ultimately supporting precision treatment for patients. Research published in the Journal of Medicinal Chemistry represents an interdisciplinary collaboration between Roland L. Dunbrack, Jr., PhD, and Ronald Levy, PhD, from Fox Chase Cancer Center’s Molecular … Continue Reading »

Fusion Biopsy Improves Detection of Prostate Cancer

The TopLine Fusion-guided biopsy combines MR images with real-time ultrasound images to create a better target for the biopsy The technology can help lower the risk of missing aggressive tumors and can avoid future unnecessary biopsies An innovative technology called MR/ultrasound fusion prostate biopsy is allowing Fox Chase physicians to take a much more targeted approach to the collection of tissue samples from patients undergoing prostate biopsies. Currently, patients with low-risk prostate cancer often choose a strategy of active surveillance, the recommended course to avoid overtreatment. Yet there is a risk of disease progression, especially if the cancer is more … Continue Reading »

Comments Off

E-mail Anonymous: A Physician’s Addiction

The following is an article by Fox Chase medical oncologist Daniel M. Geynisman, MD. The piece, published in the December 15, 2014 issue of the Journal of Clinical Oncology, discusses the pitfalls and positives of being a doctor in the age of e-mail. The next time you are sitting in Grand Rounds, standing in the cafeteria line, rounding with your team, or giving a talk, take a look at your colleagues. Chances are, they are staring at a screen, and many are probably checking e-mail. E-mail has changed how physicians communicate. Whether related to patient care, academic pursuits, or administrative … Continue Reading »

Comments Off

Helping Patients Reduce Distress

Beginning this year, the American College of Surgeons is requiring the assessment of psychological distress as part of the vital signs process. The College’s actions recognize the powerful impact of mental and behavioral health on patients’ treatment decisions and outcomes. If patients have less distress, they tend to take a more active role in their care and can do better in treatment. Fox Chase Cancer Center is going even beyond the College’s requirements to assess and treat patient distress. The Center’s new standards build on its own success in identifying and meeting patient needs through initiatives such as survivor support … Continue Reading »

Comments Off

Asbestos Exposure May Be Required to Cause Mesothelioma—Even in Patients with Risk-Increasing Mutation

While mutations in the BAP1 gene are known to increase risk for mesothelioma, new findings by Fox Chase researcher Joseph R. Testa, PhD, and colleagues indicate that asbestos exposure is also generally necessary to develop the disease. In a study published in the August 15 issue of Cancer Research, the team exposed mice with and without BAP1 mutations to asbestos, and they also followed a group of unexposed mutated mice to see if they developed any cancers. By the end of the study, 73 percent of mutated mice exposed to asbestos had developed mesothelioma, compared to only 32 percent of … Continue Reading »

Comments Off

Fox Chase-Temple Team Pursues a New Avenue in Transporter Membrane Proteins

TOPLINE Researchers identified transporter membrane protein ABCC10 as a viable target in mammary tumors; next, they will test its potential as a target in lung tumors A collaborative search for an optimized ABCC10 inhibitor is underway using molecular models Because of their ability to carry drugs out of cells, affecting biological processes such as metastasis, migration, and proliferation, transporter membrane proteins have long been a focus in cancer research. For the last 30 years, much of the research in this area has focused on P-glycoprotein, or Pgp, but after many failed studies and clinical trials, research on Pgp has fallen out … Continue Reading »

Comments Off

Vascularized Lymph Node Transfer and Lymphovenous Bypass Provide Relief from Lymphedema

The TOPLINE In vascularized lymph node transplant, the surgeon transplants healthy lymph nodes into the area affected by lymphedema Lymphatic fluid collecting in the affected extremity drains into the venous circulation, reducing swelling In lymphovenous bypass, the surgeon connects lymphatic vessels to small blood vessels to drain fluid Fox Chase surgical oncologists Sameer A. Patel, MD, FACS, and Eric I. Chang, MD, are offering vascularized lymph node transfer, an innovative surgical procedure for treating lymphedema, a common condition for patients who have had their lymph nodes removed during cancer treatment. With lymphedema occurring in the arms of up to about … Continue Reading »

Comments Off
Next Page »